ENTITY
Amgen Inc

Amgen Inc (AMGN US)

189
Analysis
Health Care • United States
Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.
more
bearish•Celltrion Inc
•15 Feb 2018 23:24

Biosimilar Battlefield: An Update

Korea's biosimilar plays, Celltrion Inc (068270 KS) , Celltrion Pharm Inc (068760 KS) , Celltrion Healthcare (091990 KS) , and Samsung Biologics...

Share
bullish•SillaJen Inc
•25 Oct 2017 14:03

SillaJen - Pipeline Review & Valuation Study

I surely understand SillaJen, Inc. (0908477D KS) is a very speculative stock to invest right now. It has virtually no revenue. We still have to...

Logo
533 Views
Share
•04 Oct 2017 00:25

Biosimilar Battlefield: U.S. Humira Pushed to 2023

We are updating our market model to reflect the patent litigation settlement between Amgen Inc (AMGN US) and Abbvie Inc (ABBV US) , the...

Share
•08 Sep 2017 10:35

Surveying The Biosimilar Battlefield

The biosimilar market has been of particular interest to us in light of the high expectations set for Samsung Biologics Co., Ltd (207940 KS)  and...

Share
bearish•Celltrion Inc
•22 Apr 2017 02:17

The Disconnect Is Growing

Celltrion Inc (068270 KS) 's Inflectra, a biosimilar to Johnson & Johnson (JNJ US) 's Remicade, had little impact on the critical U.S. market...

Share
x